We wish to correct a number of figure-related and typographical errors that appeared in the article above. None of these errors affect the conclusions of the paper.
We wish to correct a number of figure-related and typographical errors that appeared in the article above. None of these errors affect the conclusions of the paper.
In Figures 2F and S5 (upper-right), we presented two phase-contrast photos of fields of cells, correctly labeled as SCNT-derived hESO-NT1 and IVF-derived hESO-7, respectively. These images are the same fields of cells shown in the top two images of Figure 6D ; however, in Figure 6D , we inadvertently switched the labels on the images. This re-use of the images was intentional, but we should have indicated this in the original legend for Figure 6 . We have corrected the labeling error in Figure 6D .
In Figure S6 , the scatterplot presenting a comparison between biological HDF-f replicates #2 and #3 is an inadvertent duplication of the scatterplot presenting the comparison of HDF-f replicates #1 and #3. This plot has been replaced in the figure online and is shown below.
In Figure 1 , the number of SCNT embryos for I/DMAP group (n = 51) has been corrected to 53.
In Figure 5D , the numbers of plated blastocysts for agonist and antagonist were reversed and have been corrected to agonist (n = 4) and antagonist (n = 17).
In the Experimental Procedures, the age range of oocyte donors in the paper was listed as 23-31; however, the range has been corrected to 23-33.
In Table S2 , percentages for fused oocytes in the 10 nM TSA for 24 hr group (95.4) and for compact morula (CM) in the 5 nM TSA for 12 hr group (26.0) have been corrected to 96.3 and 28.0, respectively.
In Table S3 , we incorrectly reported several figures due to errors that occurred in converting the raw patient data, from which these values are calculated, from a file created with Mac-based software to a file in the analogous Windows-based software. The following corrections have been made: number of oocytes in the antagonist group 11.7 ± 5.6 has been changed to 10.2 ± 4.9; number of oocytes in the agonist group, 20.5 ± 11.9 to 16.3 ± 5.2; AMH level in the antagonist group, 2.8 ± 0.5 to 2.5 ± 0.5; AFC in the antagonist group, 23.1 ± 7.2 to 23.2 ± 7.2; FSH dosage in antagonist group, 958.3 ± 241.7 to 966.7 ± 247.3; number of hMG ampoules in antagonist group, 8.5 ± 1.6 to 10.2 ± 4.2; number of hMG ampoules in agonist group, 8.8 ± 0.9 to 8.8 ± 1.0; stimulation days in antagonist group, 8.7 ± 1.6 to 8.7 ± 0.8; and stimulation days in agonist group, 9 ± 0.8 to 9.8 ± 1.0. We have confirmed that these differences do not affect any of the statistical conclusions originally reported.
In Table S4 , short tandem repeats (STR) readings for egg donor A in D6S291 and D6S276 loci were reversed and have been corrected to 199/209 for D6S291 and 245/249 for D6S276.
Finally, when calculating percentages of SCNT embryos that reached different stages during development, the denominator employed in the calculation depended on the developmental stage, as explained below, and thus was not a constant number for all calculations. Although this is the standard in the field for these calculations, it may have caused some confusion. Therefore, we have now added the following text to the Extended Experimental Procedures to clarify the methodology for categorizing embryos at different stages:
''In Figures 1, 3, 4 , 5, and S1, percentages for 'PN' and 'Cleaved' were calculated based on the numbers of successfully reconstructed SCNT embryos provided as 'n.' Percentages for 'eight-cell,' 'CM,' and 'blastocysts' were calculated based on the number of cleaved embryos. In Table S2 , the percentage for 'fused' was calculated based on the initial number of oocytes. The percentage for 'PN' was calculated based on number of fused oocytes. The percentage for 'cleaved' was calculated based on number of PN. The percentages for 'eight-cell,' 'CM,' and 'blastocysts' were calculated based on the number of cleaved embryos. An asterisk in the graph indicates statistical significance.''
The corrections detailed here have been incorporated into the online version of the article, and they do not alter the description of the results or the main conclusions. We would also like to note that the Scientific Integrity Committee at Oregon Health & Science University has carefully assessed the paper and the errors and has concluded that there is no evidence of fabrication, falsification, or plagiarism that would warrant further inquiry or investigation into research misconduct. 
